Top

Drugs

Published in:

01-08-2007 | Adis Drug Profile

Bevacizumab in First-Line Treatment of Metastatic Breast Cancer

A Viewpoint by Xavier Pivot

Author: Xavier Pivot

Published in: Drugs | Issue 12/2007

Excerpt

Vascular endothelial growth factor (VEGF) is crucial for tumour angiogenesis and thus, the inhibition of circulating VEGF by bevacizumab seems a pertinent approach as an anticancer treatment. Whilst the key impact of bevacizumab is associated with vascular regression, the normalisation of tumour vasculature related to treatment with bevacizumab is also of interest. These changes reduce intratumoural pressure, thereby facilitating tumour exposure to chemotherapy. …

Title: Bevacizumab in First-Line Treatment of Metastatic Breast Cancer
A Viewpoint by Xavier Pivot
Author: Xavier Pivot
Publication date: 01-08-2007
Publisher: Springer International Publishing
Published in: Drugs / Issue 12/2007
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200767120-00011

At a glance: The STEP trials

Springer Medicine

Bevacizumab in First-Line Treatment of Metastatic Breast Cancer

A Viewpoint by Xavier Pivot

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 12/2007

Rasagiline

Aliskiren

Drospirenone/Ethinylestradiol 3mg/20µg (24/4 Day Regimen)

Pharmacotherapy of Mood Disorders and Treatment Discontinuation

Bevacizumab

Bevacizumab in First-Line Treatment of Metastatic Breast Cancer